Modulating Lipid Nanoparticles with Histidinamide‐Conjugated Cholesterol for Improved Intracellular Delivery of mRNA
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202303857 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Onesun Jung und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon, 34134, Republic of Korea. Hauptthemen laut MEDLINE: Cholesterol, Nanoparticles, RNA, Messenger, SARS-CoV-2. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Education, Korea Research Institute of Bioscience and Biotechnology.
Abstract (Originalsprache)
Recently, mRNA‐based therapeutics, including vaccines, have gained significant attention in the field of gene therapy for treating various diseases. Among the various mRNA delivery vehicles, lipid nanoparticles (LNPs) have emerged as promising vehicles for packaging and delivering mRNA with low immunogenicity. However, while mRNA delivery has several advantages, the delivery efficiency and stability of LNPs remain challenging for mRNA therapy. In this study, an ionizable helper cholesterol analog, 3β[L‐histidinamide‐carbamoyl] cholesterol (Hchol) lipid is developed and incorporated into LNPs instead of cholesterol to enhance the LNP potency. The p K a values of the Hchol‐LNPs are ≈6.03 and 6.61 in MC3‐ and SM102‐based lipid formulations. Notably, the Hchol‐LNPs significantly improve the delivery efficiency by enhancing the endosomal escape of mRNA. Additionally, the Hchol‐LNPs are more effective in a red blood cell hemolysis at pH 5.5, indicating a synergistic effect of the protonated imidazole groups of Hchol and cholesterol on endosomal membrane destabilization. Furthermore, mRNA delivery is substantially enhanced in mice treated with Hchol‐LNPs. Importantly, LNP‐encapsulated SARS‐CoV‐2 spike mRNA vaccinations induce potent antigen‐specific antibodies against SARS‐CoV‐2. Overall, incorporating Hchol into LNP formulations enables efficient endosomal escape and stability, leading to an mRNA delivery vehicle with a higher delivery efficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon, 34134, Republic of Korea.
- Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea.
- Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea.
- Bioscience Major, KRIBB School, Korea University of Science and Technology (UST), Daejeon, 34113, Republic of Korea.
ORCID-Profile: Eunjung Lee, Joon Sig Choi
Förderung
- National Research Foundation of Korea
- Ministry of Education
- Korea Research Institute of Bioscience and Biotechnology
Zitieren
APA
Jung, O., Jung, H. Y., Thuy, L. T., Choi, M., Kim, S., Jeon, H. G., Yang, J., Kim, S. M., Kim, T. D., Lee, E., Kim, Y., & Choi, J. S. (2024). Modulating Lipid Nanoparticles with Histidinamide‐Conjugated Cholesterol for Improved Intracellular Delivery of mRNA. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202303857
Vancouver
Jung O, Jung HY, Thuy LT, Choi M, Kim S, Jeon HG, et al. Modulating Lipid Nanoparticles with Histidinamide‐Conjugated Cholesterol for Improved Intracellular Delivery of mRNA. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202303857
BibTeX
@article{Jung2024,
author = {Jung, Onesun and Jung, Hye-Youn and Thuy, Le Thi and Choi, Minyoung and Kim, Seongyeon and Jeon, Hae-Geun and Yang, Jihyun and Kim, Seok-Min and Kim, Tae-Don and Lee, Eunjung and Kim, Yoonkyung and Choi, Joon Sig},
title = {Modulating Lipid Nanoparticles with Histidinamide‐Conjugated Cholesterol for Improved Intracellular Delivery of mRNA},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202303857}
}
EUVIMED